Bruce Lehman, one of the longest-serving CEOs in the medical agency world, will retire at year’s end, agency officials confirmed, spurring new leadership at the firm he co-founded in 1978, LehmanMillet.
Novo redoubled its Victoza marketing efforts after a recent setback, and that’s made things tougher for GLP-1 rivals Bristol-Myers Squibb and AstraZeneca.
Business briefs: GlaxoSmithKline and Spectrum
August 5, 2013
8:41 pm
GSK sees a regulatory setback on its once-weekly GLP-1 med, and Spectrum Pharma gets hit with an untitled letter from OPDP on a sales aid for Zevalin.
Drug makers say the AMA’s labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands’ messaging.
Marci Piasecki was promoted to regional director, North America, with oversight over all five US professional agencies in McCann Health, the most senior of a series of personnel moves the network said are designed to bolster the operation.
Navidea deploying MSLs in launch of new diagnostic agent
Medical science liaisons will educate nuclear-medicine clinicians as part of the launch of a new Navidea diagnostic agent for use in breast and skin cancer.
Business briefs: BMS, Sanofi, UK Sunshine
April 8, 2013
4:57 pm
BMS fills week’s end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year.
